Published: September, 2015 Authors:Sumudu K. Narayana, Karla J. Helbig,Erin M. McCartney, Nicholas S. Eyre, Rowena A. Bull, Auda Eltahla, Andrew R. Lloyd and Michael R. Beard Source: Journal of Biology Chemistry Abstract:The interferon-induced transmembrane (IFITM) family of proteins have recently been identified as important host effector molecules of the type…
Read More
October 30, 2015 Gilead Sciences has filed a new drug application with the U.S. Food and Drug Administration (FDA) for approval of the once-daily, fixed-dose combination tablet of Sovaldi (sofosbuvir) and the investigational drug velpatasvir to treat those with genotypes 1 through 6 of hepatitis C virus (HCV). The application…
Read More
October 29, 2015 A generic version of hepatitis C virus (HCV) treatment sofosbuvir will soon hit the market in Morocco at a much lower cost than existing brand-name versions of the pill, Morocco World News reports. The soon-to-be-released “100% Moroccan” drug—which contains the same active ingredients as Gilead Sciences’ brand-name…
Read More
20th October 2015 A new smartphone app from Children’s Liver Disease Foundation (CLDF) will enable health visitors to identify the signs of serious liver disease in newborn babies more quickly and easily. The app, which has been endorsed by Public Health England and the Institute of Health Visiting, is the…
Read More
October 27, 2015 Compared to the overall population of those living with hepatitis C virus (HCV), injection drug users (IDUs) tend to be much younger when they develop serious liver damage from HCV, show new findings published in the International Journal of Drug Policy and reported by New York University,…
Read More
October 23, 2015 The U.S. Food and Drug Administration (FDA) has required AbbVie to change the labels for its two hepatitis C virus (HCV) treatments after receiving numerous reports of serious liver injury developing among people while taking the medications, Medscape reports. Previously, the labels for Viekira Pak (ombitasvir/paritaprevir/ritonavir; dasabuvir)…
Read More
October 26, 2015 Injection drug users (IDUs) who participate in opioid substitution therapy (OST) programs are at lower risk of contracting hepatitis C virus (HCV), especially if they also receive significant injection supplies from a needle exchange program (NEP), aidsmap reports. These findings, the result of a systematic review of…
Read More
Oct 22, 2015 WASHINGTON (AP) — Federal health officials are warning doctors and patients that two hepatitis C drugs from AbbVie can cause life-threatening liver injury in patients with advanced forms of the disease. The Food and Drug Administration said Thursday it will require AbbVie to add new warnings to…
Read More
October 23, 2015 Bristol-Myers Squibb has announced the 2015 recipients for three $300,000 research grants under its Partnering for Cure program, which this year, will go toward providing new insights on the immunopathology of HIV and the hepatitis B virus (HBV), according to a recent press release from the pharmaceutical…
Read More
October 22, 2015 Johnson & Johnson (J&J) recently won its first lawsuit over the link between its Tylenol painkiller and liver damage caused by taking too much of the over-the-counter drug, Bloomberg reports. A jury in New Jersey concluded that Regina Jackson, 55, who spent a week in the hospital…
Read More